Diabetes

A patient-centered approach on top of a multifactorial approach will help patients adhere to lifestyle modifications, said Nikolaus Marx, MD, professor of medicine/cardiology and head of the Department of Internal Medicine, University Hospital Aachen, Germany.

Analysis of claims data showed reduced utilization and costs among patients with nonintensively managed type 2 diabetes using self-monitoring of blood glucose compared with continuous glucose monitoring.

A statistical model based entirely on claims data can accurately predict 30-day hospital readmission in Medicaid patients with diabetes.

Management of empagliflozin and ertugliflozin may be suboptimal following an insurance carrier’s formulary updates. Pharmacists may improve the management.

CMS began reimbursement for non–face-to-face chronic care management in 2015, and results from Louisiana show that it increases outpatient visits but decreases inpatient and emergency department encounters.

According to one panelist, the leading causes of hypoglycemia in older adults are insufficient nutrition and taking the wrong dose or type of insulin, both of which can be addressed at the patient and system level.

A Hong Kong study revealed how much type 2 diabetes (T2D) can increase hospital bed-days based on condition, age, sex, and other factors.

Panelists at the American Diabetes Association 83rd Scientific Sessions explained how time in range is emerging as a crucial target in diabetes management.

Thousands more people filled their insulin prescriptions following the introduction of the cap in January 2023, especially compared to those who were not enrolled in Medicare, a new study finds.

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.

An analysis of electronic health record data recorded from 2018-2022 within Duke University Medical Center–affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.

While the overall age-adjusted mortality rate for diabetes and cardiovascular disease (CVD) declined between 1999 and 2019, researchers found an average annual 1% increase since 2014.

According to a Kaiser Family Foundation analysis, 22% of Medicare Part D drug spending in 2021 went towards the 10 top-selling prescription drugs alone.

There may be significant differences in kidney disease between individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D).

Late-breaking results of the COORDINATE-Diabetes trial were presented today at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego, California.

New estimates predict that type 2 diabetes prevalence will more than double in the next 30 years, from 529 million people in 2021 to at least 1.3 billion in 2050.

Yesterday’s FDA approvals of a new indication for empagliflozin and combination empagliflozin with metformin hydrochloride for pediatric type 2 diabetes (T2D) provide a new class of oral drugs to treat the condition in children.

Among a small cohort of healthy Korean male volunteers, evogliptin combined with empagliflozin or dapagliflozin had no significant effects on the pharmacokinetics (PK) of each drug.

According to a spokesperson, Merck is prepared to take the lawsuit to the Supreme Court as it challenges drug price negotiations as part of the Inflation Reduction Act.

The authors examined the association of diabetes with self-reported gaps in care coordination and self-reported preventable adverse events using data from a national sample of older adults.

Amal Agarwal, DO, MBA, chief clinical officer at Monogram Health, explains the importance of value-based agreements in dialysis care, and the issue of dialysis prevalence among low-income and marginalized communities.

This article describes facilitators of and barriers to uptake of the underutilized Medicare Diabetes Prevention Program from the perspectives of health care providers and program suppliers in western Pennsylvania.

Using propensity score matching in a US nationally representative sample, authors found the effect of nonadherence to diabetes guidelines on health care expenditures of patients with diabetes.

A review of 24 meta-analyses supported the need for additional monitoring of patients with diabetes and COVID-19, especially if they have comorbidities associated with diabetes.

Authors offered specific recommendations for improving publishing and adoption of algorithmic processes focused on type 2 diabetes (T2D) going forward.

Knowledge is limited on the potential exclusion from pay-for-performance (P4P) programs of patients living with diabetes who have with individual or neighborhood social risks.

Study authors said the findings could inform clinicians when selecting therapies for patients with type 2 diabetes (T2D). However, an editorial found the follow-up period too short and differences between the study arms too small to be meaningful.

Diabetes risk perception was linked to increased TV watching and 1 less day per week of at least 60 minutes of exercise, and was not associated with nutrition or weight loss attempts among adolescents.

Investigators said data show social factors are intertwined with health outcomes.